Skip to content

Effectiveness of Contrast-Enhanced Harmonic Endoscopic Ultrasound for the predicts pathological grade of solid pancreatic cancer

Effectiveness of Contrast-Enhanced Harmonic Endoscopic Ultrasound for the predicts pathological grade of solid pancreatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031180
Enrollment
Unknown
Registered
2020-03-23
Start date
2020-04-09
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Gold Standard:Pathologic diagnosis
Ultrasound

Sponsors

Zhongnan hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-80 years; 2. All patients with pancreatic tumors on computed tomography or magnetic resonance imaging requiring cytohistological evidence; 3. Patients willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with serious heart and lung diseases and severe renal insufficiency; 2. Patients with abnormal clotting function, or those who take antiplatelet or anticoagulant drugs orally without stopping; 3. Patients with cystic lesions to be punctured.

Design outcomes

Primary

MeasureTime frame
Vascular patterns;avascular areas;SEN, SPE, ACC, AUC of ROC;

Secondary

MeasureTime frame
Histology of PC;

Countries

China

Contacts

Public ContactZhao Qiu

Zhongnan Hospital

zhaoqiu2020@163.com+86 13761491681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026